BRIEF-Emergent Biosolutions Inc - ‍announced a licensing agreement with Valneva SE for global exclusive rights to Valneva's zika vaccine technology, ZIKV​

July 26 (Reuters) - Emergent Biosolutions Inc

* Emergent Biosolutions Inc - announced a licensing agreement with Valneva SE for global exclusive rights to Valneva’s zika vaccine technology, ZIKV

* Emergent biosolutions inc - emergent and valneva will co-develop zikv-vla1601

* Emergent Biosolutions Inc - under terms of agreement, emergent will pay Valneva eur 1 million upfront

* Emergent Biosolutions Inc - companies plan to initiate phase 1 trial in late 2017 or early 2018

* Emergent Biosolutions - cos will share all costs until availability of phase 1 data, which is anticipated within six months from trial initiation

* Emergent - will have option to continue development arrangement with valneva for a milestone payment of eur 5 million, upon availability of phase 1 data

* Emergent Biosolutions Inc - agreement also provides valneva potential additional milestone payments of up to eur 44 million

* Emergent Biosolutions Inc - companies are expected to enter into a technology transfer agreement at a later time Source text for Eikon: Further company coverage: